Skip to main content
. 2017 Sep 18;292(44):18325–18343. doi: 10.1074/jbc.M117.801514

Table 1.

Summary of the properties of the two therapeutic antibodies solanezumab and crenezumab

Solanezumab Crenezumab
Epitope Aβ12–28 Aβ12–23
Aβ form Monomeric Monomeric, oligomers, and fibrils
Affinity Picomolar level Nanomolar level
Template IgG1 IgG4
CDR-L1 RSSQSLIYSDGNAYLHTFL RSSQSLVYSNGDTYLHTYL
CDR-L2 KVSNRFS KVSNRFS
CDR-L3 SQSTHVPWT SQSTHVPWT
CDR-H1 GFTFSRYSMS GFTFSSYGMS
CDR-H2 QINSVGNSTYYPDTVKGRFT SINSNGGSTYYPDSVKGRFT
CDR-H3 GDY GDY